For 25 years, I’ve had Type 1 diabetes. Like the tens of millions of Americans with diabetes, one of the most important things I have to do to stay healthy is make sure my blood sugar is in normal range.
Continuous glucose monitors (CGMs) allow diabetics to track their blood sugar 24/7. They’re incredibly useful, providing insight on how your blood sugar reacts to insulin, food, exercise and whatever else affects it.
Abbott Laboratories and Dexcom are the leaders in the CGM market, which hit $5.1 billion in revenue in 2021 and is expected to reach $13.2 billion by 2028, according to Vantage Market Research. Abbott’s CGM systems, called FreeStyle Libre, generated $3.7 billion in revenue last year, with 4 million users globally.
Abbott has just released its newest CGM, the FreeStyle Libre 3. It comes with an important upgrade. Whereas the previous systems were “flash” CGMs, which means you had to hold your reader or phone close to the sensor to get a reading, the new version sends data straight to your phone.
I tried it out for over a month. Here are my takeaways:
How it works
The insertion device comes in a small box and is rather compact. The Libre 3 is only approved by the Food and Drug Administration to go into the arm. The insertion was painless, and the sensor itself is tiny compared to others I’ve used.
CNBC’s Erin Black tests new CGM Abbott Freestyle Libre 3
CNBC | Erin Black
The app requires a scan of the sensor, and then it takes 60 minutes to warm up. During the first 12 hours, a blood drop icon will appear.
Abbott Freestyle Libre 3 iPhone app
CNBC | Andrew Evers
Abbott says the sensor is acclimating. It also advises using a blood glucose meter to ensure the sensor is accurate. I found that it was accurate immediately, even while it was warming up.
Abbott Freestyle Libre 3
CNBC | Erin Black
The sensor stays on for 14 days. It gives a new reading every minute, compared to a reading every five minutes from the Dexcom G6. The adhesive worked well and showed no sign of falling off after two weeks. It still doesn’t require finger sticks or calibration.
Abbott Freestyle Libre 3 sensor
CNBC | Andrew Evers
The trend arrows tell you if your glucose is steady, rising or falling. The alarms are customizable. If you want to silence low and high alerts, you can use the app’s “do not disturb” function. The urgent low alarm can’t be silenced, as required by the FDA.
The app has some useful features for tracking average glucose and time in range and gives you the option to share the data with loved ones. It also has a reports feature that gives you insights into patterns so you can make dosage adjustments.
The Libre 3 is small and accurate
I love how small it is, so small in fact that I kept forgetting I was wearing it. I put my Dexcom G6 nearby to compare. There’s a big difference.
Abbott Freestyle Libre 3 size vs Dexcom G6
CNBC | Erin Black
It was accurate most of the time. But I found that during times of rapid change, such as when I forgot to take my insulin after a meal, it became inaccurate and had a hard time keeping up.
I did have two compression lows with the first sensor. A compression low is when the sensor gives an incorrect low reading. One occurred while I was sleeping on my side, and the other was while I was sitting on the couch and leaning on the sensor. I readjusted, and the device quickly corrected itself. I made sure to choose a better placement for the second sensor.
The app can be improved
In the app, you can’t customize the graph size. It shows a range of 50 mg/dL to 350 mg/dl. I’d like the ability to adjust that so it’s a little tighter, because my blood sugar rarely goes above 250 mg/dl, so there’s a lot of wasted space.
There’s also no ability to zoom into past readings. Sometimes when I’m low I like to be able to zoom in and see how quickly the number is changing. And while it does send notifications to my iWatch, Abbott doesn’t yet have an app compatible to use with it, so seeing your blood sugar on your watch isn’t possible. Abbott says it’s something they’re working on for the future.
Abbott Freestyle Libre 3 Apple iWatch notification
CNBC | Erin Black
Prescription required, price varies
The Libre 3 requires a prescription, so the cost will be different for everyone. Abbott said users with insurance can expect to pay $0-$25 per sensor and $70 per sensor without insurance. You’ll need to buy two a month.
Would I recommend this to other diabetics? Yes, but it depends on the user. For diabetics like me who use insulin pumps, the Libre 3 isn’t compatible yet. Abbott said it’s working on pump integration with Tandem Diabetes and Insulet. The company is also working with Bigfoot Biomedical on integration with its insulin delivery system.
For diabetics who rely on manual insulin injections or who diet to manage their diabetes, this is a great way to monitor blood sugar.
OpenAI on Friday introduced a new program, dubbed the “OpenAI Grove,” for early tech entrepreneurs looking to build with artificial intelligence, and applications are already open.
Unlike OpenAI’s Pioneer Program, which launched in April, Grove is aimed towards individuals at the very nascent phases of their company development, from the pre-idea to pre-seed stage.
For five weeks, participants will receive mentoring from OpenAI technical leaders, early access to new tools and models, and in-person workshops, located in the company’s San Francisco headquarters.
Roughly 15 members will join Grove’s first cohort, which will run from Oct. 20 to Nov. 21, 2025. Applicants will have until Sept. 24 to submit an entry form.
CNBC has reached out to OpenAI for comment on the program.
Following the program, Grove participants will be able to continue working internally with the ChatGPT maker, which was recent valued $500 billion.
Nurturing these budding AI companies is just a small chip in the recent massive investments into AI firms, which ate up an impressive 71% of U.S. venture funding in 2025, up from 45% last year, according to an analysis from J.P. Morgan.
AI startups raised $104.3 billion in the U.S. in the first half of this year, and currently over 1,300 AI startups have valuations of over $100 million, according to CB Insights.
The co-founder and CEO of sales and customer service management software company Salesforce is well aware that investors are betting big on Palantir, which offers data management software to businesses and government agencies.
“Oh my gosh. I am so inspired by that company,” Benioff told CNBC’s Morgan Brennan in a Tuesday interview at Goldman Sachs‘ Communacopia+Technology conference in San Francisco. “I mean, not just because they have 100 times, you know, multiple on their revenue, which I would love to have that too. Maybe it’ll have 1000 times on their revenue soon.”
Salesforce, a component of the Dow Jones Industrial Average, remains 10 times larger than Palantir by revenue, with over $10 billion in revenue during the latest quarter. But Palantir is growing 48%, compared with 10% for Salesforce.
Benioff added that Palantir’s prices are “the most expensive enterprise software I’ve ever seen.”
“Maybe I’m not charging enough,” he said.
Read more CNBC tech news
It wasn’t Benioff’s first time talking about Palantir. Last week, Benioff referenced Palantir’s “extraordinary” prices in an interview with CNBC’s Jim Cramer, saying Salesforce offers a “very competitive product at a much lower cost.”
The next day, TBPN podcast hosts John Coogan and Jordi Hays asked for a response from Alex Karp, Palantir’s co-founder and CEO.
“We are very focused on value creation, and we ask to be modestly compensated for that value,” Karp said.
The companies sometimes compete for government deals, and Benioff touted a recent win over Palantir for a U.S. Army contract.
Palantir started in 2003, four years after Salesforce. But while Salesforce went public in 2004, Palantir arrived on the New York Stock Exchange in 2020.
Palantir’s market capitalization stands at $406 billion, while Salesforce is worth $231 billion. And as one of the most frequently traded stocks on Robinhood, Palantir is popular with retail investors.
Salesforce shares are down 27% this year, the worst performance in large-cap tech.
Gemini Co-founders Tyler Winklevoss and Cameron Winklevoss attend the company’s IPO at the Nasdaq MarketSite in New York City, U.S., Sept. 12, 2025.
Jeenah Moon | Reuters
Shares of Gemini Space Station soared more than 40% on Thursday after the exchange operator raised $425 million in an initial public offering.
The stock opened at $37.01 on the Nasdaq after its IPO priced at $28. At one point, shares traded as high as $40.71.
The New York-based company priced its IPO late Thursday above this week’s expected range of $24 to $26, and an initial range of between $17 and $19. That valued the company at some $3.3 billion before trading began.
Gemini, which primarily operates as a cryptocurrency exchange, was founded by the Winklevoss brothers in 2014 and held more than $21 billion of assets on its platform as of the end of July. Per its registration with the Securities and Exchange Commission, Gemini posted a net loss of $159 million in 2024, and in the first half of this year, it lost $283 million.
The company also offers a U.S. dollar-backed stablecoin, credit cards with a crypto-back rewards program and a custody service for institutions.
The Winklevoss brothers were among the earliest bitcoin investors and first bitcoin billionaires. They have long held that bitcoin is a superior store of value than gold. On Friday morning, they told CNBC’s “Squawk Box” they see its price reaching $1 million a decade from now.
In 2013, they were the first to apply to launch a bitcoin exchange-traded fund, more than 10 years before the first bitcoin ETFs would eventually be approved. The Securities and Exchange Commission’s rejection of the application, which cited risk of fraud and market manipulation, set the stage for the bitcoin ETF debate in the years to come.
Even in the early days, when bitcoin was notorious for its extreme volatility and anti-establishment roots and shunned by Wall Street, the Winklevoss brothers were outspoken about the need for smart regulation that would establish rules for the crypto-led financial revolution.
Don’t miss these cryptocurrency insights from CNBC Pro:
(Learn the best 2026 strategies from inside the NYSE with Josh Brown and others at CNBC PRO Live. Tickets and info here.)